Albertson, D. (Donna G.)

Filtering

2007 - 20092

Settings

Author search.filters.isAuthorOfPublication.ca9e1f3c-3094-41f3-8bdc-b06d2c3dc7a3

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Deletion of chromosome 11q predicts response to anthracycline-based chemotherapy in early breast cancer
    (American Association for Cancer Research, 2007) Palacios, J. (José); Fridlyand, J. (J.); Pinkel, D. (Daniel); Martinez-Climent, J.A. (José Ángel); Dimitrow, P. (P.); Siebert, R. (Reiner); Climent, J. (Javier); Lluch, A. (Ana); Albertson, D. (Donna G.); Gray, J.W. (Joe W.)
    Despite the recent consensus on the eligibility of adjuvant systemic therapy in patients with lymph node–negative breast cancer (NNBC) based on clinicopathologic criteria, specific biological markers are needed to predict sensitivity to the different available therapeutic options.W e examined the feasibility of developing a genomic predictor of chemotherapy response and recurrence risk in 185 patients with NNBC using assembled arrays containing 2,460 bacterial artificial chromosome clones for scanning the genome for DNA copy number changes.Aft er surgery, 90 patients received anthracyclinebased chemotherapy, whereas 95 did not.T amoxifen was administered to patients with hormone receptor–positive tumors. The association of genomic and clinicopathologic data and outcome was computed using Cox proportional hazard models and multiple testing adjustment procedures.Analysis of NNBC genomes revealed a common genomic signature.Specific DNA copy number aberrations were associated with hormonal receptor status, but not with other clinicopathologic variables. In patients treated with chemotherapy, none of the genomic changes were significantly correlated with recurrence.In patients not receiving chemotherapy, deletion of eight bacterial artificial chromosome clones clustered to chromosome 11q was independently associated with relapse (disease-free survival at 10 years F SE, 40% F 14% versus 86% F 6%; P < 0.0001). The 54 patients with deletion of 11q (29%) did not present more aggressive clinicopathologic features than those without 11q loss.The adverse influence of 11q deletion on clinical outcome was confirmed in an independent validation series of 88 patients with NNBC.Our data suggests that patients with NNBC with the 11q deletion might benefit from anthracycline-based chemotherapy despite other clinical, pathologic, or genetic features.However , these initial findings should be evaluated in randomized clinical trials.
  • No Thumbnail Available
    Co-amplified genes at 8p12 and 11q13 in breast tumors cooperate with two major pathways in oncogenesis
    (Nature Publishing Group, 2009) Fridlyand, J. (J.); Martinez-Climent, J.A. (José Ángel); Zhou, H. (H.); Climent, J. (Javier); Albertson, D. (Donna G.); Roy, R. (R.); Kwek, S.S. (S. S.)
    Co-amplification at chromosomes 8p11-8p12 and 11q12-11q14 occurs often in breast tumors, suggesting possible cooperation between genes in these regions in oncogenesis. We used high-resolution array comparative genomic hybridization (array CGH) to map the minimal amplified regions. The 8p and 11q amplicons are complex and consist of at least four amplicon cores at each site. Candidate oncogenes mapping to these regions were identified by combining copy number and RNA and protein expression analyses. These studies also suggested that CCND1 at 11q13 induced expression of ZNF703 mapping at 8p12, which was subsequently shown to be mediated by the Rb/E2F pathway. Nine candidate oncogenes from 8p12 and four from 11q13 were further evaluated for oncogenic function. None of the genes individually promoted colony formation in soft agar or collaborated with each other functionally. On the other hand, FGFR1 and DDHD2 at 8p12 cooperated functionally with MYC, whereas CCND1 and ZNF703 cooperated with a dominant negative form of TP53. These observations highlight the complexity and functional consequences of the genomic rearrangements that occur in these breast cancer amplicons, including transcriptional cross-talk between genes in the 8p and 11q amplicons, as well as their cooperation with major pathways of tumorigenesis.